Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

NCT01055314 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

175

Enrollment

NIH

Sponsor class

Conditions

Adult Rhabdomyosarcoma
Childhood Alveolar Rhabdomyosarcoma
Childhood Embryonal Rhabdomyosarcoma
Metastatic Childhood Soft Tissue Sarcoma
Stage IV Adult Soft Tissue Sarcoma
Untreated Childhood Rhabdomyosarcoma

Interventions

BIOLOGICAL: Cixutumumab
DRUG: Cyclophosphamide
BIOLOGICAL: Dactinomycin
DRUG: Doxorubicin Hydrochloride
DRUG: Etoposide
DRUG: Ifosfamide
DRUG: Irinotecan Hydrochloride
OTHER: Laboratory Biomarker Analysis
DRUG: Temozolomide
DRUG: Vincristine Sulfate Liposome

Sponsor

National Cancer Institute (NCI)